← Back to all signals
RESEARCH PAPER ANALYSIS

Classification of fall risk in Parkinson's disease using empirical mode decomposition and machine learning.

This study used empirical mode decomposition of center-of-pressure signals and machine learning (SFFS feature selection plus classifiers) to classify fall risk in 32 PD patients, identifying a 3-feature subset and achieving up to 0.96 subject-level AUC in the best condition.

PMID41938060
JournalFrontiers in bioengineering and biotechnology
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This study used empirical mode decomposition of center-of-pressure signals and machine learning (SFFS feature selection plus classifiers) to classify fall risk in 32 PD patients, identifying a 3-feature subset and achieving up to 0.96 subject-level AUC in the best condition.

WHY IT MATTERS

Research significance

Offers a robust, objective monitoring/stratification tool for fall risk and potential clinical-trial endpoints in PD, improving assessment and remote monitoring, but provides little direct mechanistic or therapeutic discovery insight.

ABSTRACT

Source abstract

INTRODUCTION: Fall risk assessment in Parkinson's Disease (PD) is critical for preventing patient injuries; however, traditional clinical scales are often constrained by their semi-quantitative nature and time-consuming administration. This study aimed to develop and validate an analytical framework integrating Empirical Mode Decomposition (EMD) and machine learning for the objective classification of fall risk in PD patients. METHODS: Data from 32 PD patients under four standing conditions were analyzed, with fall risk labels defined based on a Mini-BESTest score cutoff of ≤21. Center of Pressure (COP) signals were first decomposed into Intrinsic Mode Functions (IMFs) using EMD, from which multi-dimensional features were extracted. Subsequently, the Sequential Forward Floating Selection (SFFS) algorithm was employed to identify a core feature subset, and the performance of five classifiers-Random Forest (RF), Decision Tree (DT), Extreme Gradient Boosting (XGB), Logistic Regression (LR), and Support Vector Machine (SVM)-was evaluated using Leave-One-Subject-Out Cross-Validation (LOSO-CV). Finally, a multi-trial probability aggregation strategy was introduced to assess subject-level risk. RESULTS: Results indicated that the rigid surface eyes-closed (rs ec) condition yielded the optimal discriminatory capability. The SFFS algorithm identified a parsimonious 3-dimensional feature subset (COPap_IMF1_BinEntropy, COPml_IMF1_STD, COPap_IMF2_TotalPower), which enabled tree-based classifiers to exhibit superior performance. Notably, DT and RF achieved highly balanced sensitivity and specificity, reaching a maximum subject-level AUC of 0.96. DISCUSSION: In conclusion, EMD-derived multi-scale features can precisely capture postural control deficits in PD, offering a promising technical solution for the future development of efficient and objective PD clinical monitoring tools.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic